Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. ACAD | 0.00 |
Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:
ACAD) with a Hold and raises the price target from $24 to $25.